

EPIX Pharmaceuticals, Inc.  
Form 8-K  
October 05, 2005

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT**

**TO SECTION 13 OR 15(D) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**



Date of report (Date of earliest event reported): **October 5, 2005**

## **EPIX Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 8-K

(State or Other Jurisdiction of Incorporation)

**000-21863**

(Commission File Number)

**04-3030815**

(IRS Employer Identification No.)

**161 First Street, Cambridge, Massachusetts**

**02142**

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 8-K

(Address of Principal Executive Offices)

(Zip Code)

**(617) 250-6000**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On October 5, 2005, EPIX Pharmaceuticals, Inc. issued a press release announcing that its worldwide marketing partner, Schering AG, Germany, has received the approval of Vasovist<sup>®</sup> (MS-325, gadofosveset trisodium) in all 25 member states of the EU. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

(c) The following exhibits are furnished with this report:

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated October 5, 2005.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**EPIX Pharmaceuticals, Inc.**

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form 8-K

(Registrant)

Date: October 5, 2005

/s/ Michael J. Astrue  
Michael J. Astrue  
*Chief Executive Officer*

3

---